Details of the Drug

General Information of Drug (ID: DMZJNHM)

Drug Name
SYNB1891
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Neoplasm 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD ID
DUR0F6
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Stimulator of interferon genes protein (TMEM173) TTT402Y STING_HUMAN Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04167137) Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects. U.S. National Institutes of Health.
2 Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020 Jun 1;11(1):2739.